NewsZydus Lifesciences Subsidiary ZVTEC Receives CGST Demand Order of Rs. 9.00 Million for Alleged Inadmissible Input Tax CreditZydus Lifesciences Subsidiary ZVTEC Receives CGST Demand Order of Rs. 9.00 Million for Alleged Inadmissible Input Tax Credit
Zydus VTEC Limited (ZVTEC), a wholly owned subsidiary of Zydus Lifesciences Limited, received a CGST demand and penalty order of Rs. 9.00 million each from the Deputy Commissioner of CGST & Central Excise, Ahmedabad North Commissionerate, on May 4, 2026. The order, passed under Section 74 of the CGST Act, 2017, relates to alleged inadmissible Input Tax Credit availment for the period September 2020 to March 2023. Zydus Lifesciences has stated its intention to appeal the order and confirmed there is no material financial impact on ZVTEC or the company.
*this image is generated using AI for illustrative purposes only.
Zydus Lifesciences Limited has disclosed, under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, that its wholly owned subsidiary, Zydus VTEC Limited (ZVTEC), has received a demand Order-In-Original from the Deputy Commissioner of CGST & Central Excise, Ahmedabad North Commissionerate. The order was received at 11:21 a.m. on May 4, 2026, and the disclosure was filed on May 5, 2026.
Nature of the Demand Order
The order has been passed under Section 74 of the CGST Act, 2017, and pertains to the period from September 2020 to March 2023. The authority has raised a demand and imposed a penalty of Rs. 9.00 million each on ZVTEC, citing alleged availment of inadmissible Input Tax Credit during the said period. The key details of the order as disclosed are summarised below:
| Parameter: | Details |
|---|---|
| Authority: | Deputy Commissioner of CGST & Central Excise, Ahmedabad North Commissionerate |
| Nature of Order: | Demand and penalty under Section 74 of CGST Act, 2017 |
| Demand Amount: | Rs. 9.00 million |
| Penalty Amount: | Rs. 9.00 million |
| Period Covered: | September 2020 to March 2023 |
| Date of Receipt: | 11:21 a.m. on May 4, 2026 |
| Alleged Violation: | Inadmissible Input Tax Credit availment |
Company's Response and Financial Impact
Zydus Lifesciences has stated that ZVTEC firmly believes the matter has strong merits and intends to appeal against the order. The company has cited past precedents of High Court and Supreme Court judgments on the matter, expressing confidence in obtaining a favourable outcome on appeal.
With respect to the financial implications, the company has clarified that there is no material financial impact on either ZVTEC or on Zydus Lifesciences Limited as a result of this order.
Regulatory Disclosure
The disclosure was made in compliance with Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and the SEBI Master Circular dated January 30, 2026. The filing was signed by Dhaval N. Soni, Company Secretary and Compliance Officer of Zydus Lifesciences Limited (Membership No. FCS7063).
Historical Stock Returns for Zydus Life Science
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -0.03% | +5.40% | +7.62% | -0.43% | +6.08% | +55.84% |
How might a prolonged appellate process against this CGST demand order affect Zydus VTEC Limited's operational cash flows and tax provisioning strategy in upcoming quarters?
Are there other Zydus Lifesciences subsidiaries currently facing similar Input Tax Credit scrutiny under Section 74 of the CGST Act that could aggregate into a more material financial exposure?
What precedent could the High Court or Supreme Court judgments cited by Zydus set for the broader pharmaceutical industry's approach to Input Tax Credit claims during the 2020–2023 period?
20
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
